Results 91 to 100 of about 75,915 (258)

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source

Studies on Regioselective Binding Mode of Steroid Molecules in Homology Modeled Cytochrome P450-2C11 [PDF]

, 2009
In this study, we investigated the regioselective binding mode of steroid molecules and structure requirements for steroid molecules for 16[alpha]-hydroxylation by Cytochrome P450-2C11.
Eiichi Akaho, Hamed I. Ali, Hukihisa Fujita, Morio Yamada   +3 more
core   +1 more source

Flavonoids as CYP3A4 Inhibitors In Vitro

Biomedicines
Flavonoids, a diverse group of polyphenolic compounds found abundantly in fruits, vegetables, and beverages like tea and wine, offer a plethora of health benefits. However, they have a potential interaction with drug metabolism, particularly through the inhibition of the cytochrome P450 3A4 enzyme, the most versatile and abundant enzyme in the liver ...
Martin Kondža, Ivica Brizić, Stela Jokić   +2 more
openaire   +4 more sources

Exposure to CYP3A4‐inducing and CYP3A4‐non‐inducing antiepileptic agents and the risk of fractures [PDF]

Pharmacoepidemiology and Drug Safety, 2011
ABSTRACTPurposeTo evaluate whether exposure to Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)‐inducing antiepileptics increases fracture risk compared to CYP3A4‐non‐inducing antiepileptics.MethodsWe performed a retrospective cohort study of initiators of antiepileptic agents using a UK medical record database (The Health Improvement ...
Hedi, Schelleman, John R, Pollard, Craig, Newcomb, Clyde E, Markowitz, Warren B, Bilker, Mary B, Leonard, Sean, Hennessy   +6 more
openaire   +2 more sources

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh, Kate Hanrott, Olof Breuer, Johan Bylund, Björn Schultze, Virginia Norris   +5 more
wiley   +1 more source

Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level. [PDF]

, 2020
The interest in vitamin D continues unabated with thousands of publications contributing to a vast and growing literature each year. It is widely recognized that the vitamin D receptor (VDR) and the enzymes that metabolize vitamin D are found in many ...
Bikle, Daniel D
core   +1 more source

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]

, 2016
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R, Faragon, John, McLaughlin, Milena, Morse, Caroline, Patel, Nimish   +4 more
core   +2 more sources

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio

Clinical Pharmacology &Therapeutics, EarlyView.
Cinnamon (Cinnamomum spp.) is used as a culinary spice and dietary supplement. A major constituent, cinnamaldehyde, was previously shown to inactivate cytochrome P450 (CYP) 2A6 in vitro. A mechanistic static model predicted an ~5‐fold increase in the AUC of the CYP2A6 substrates nicotine and letrozole.
Aiden‐Hung P. Nguyen, Deena L. Hadi, Daniel A. Todd, Preston K. Manwill, John R. White, Matthew E. Layton, Nadja B. Cech, Kenneth E. Thummel, Mary F. Paine   +8 more
wiley   +1 more source

Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin\u27s lymphoma (AMC-075) [PDF]

, 2018
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma.
Aboulafia, David, Ambinder, Richard F, Cesarman, Ethel, Henry, David, Lee, Jeanette Y, Mitsuyasu, Ronald, Moore, Page C, Noy, Ariela, Ramos, Juan C, Ratner, Lee, Reid, Erin G, Rudek, Michelle A, Sparano, Joseph A   +12 more
core   +2 more sources

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source